Trials / Terminated
TerminatedNCT00395057
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN 211745 | AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2 |
| DRUG | AGN 211745 | AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2 |
| DRUG | AGN 211745 | AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2 |
| DRUG | Ranibizumab 500µg | Ranibizumab 500µg injections at Day 1, Month 1, Month 2 |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-10-01
- Completion
- 2009-02-01
- First posted
- 2006-11-02
- Last updated
- 2015-09-07
- Results posted
- 2011-12-13
Locations
3 sites across 3 countries: United States, Australia, Philippines
Source: ClinicalTrials.gov record NCT00395057. Inclusion in this directory is not an endorsement.